OBJECT DRUGS

Phosphodiesterase Inhibitors:

• Avanafil (Stendra)
• Sildenafil (Viagra, etc.)
• Tadalafil (Cialis, etc.)
• Vardenafil (Levitra, etc.)

PRECIPITANT DRUGS

Enzyme Inducers:

• Barbiturates
• Bosentan (Tracleer)
• Carbamazepine (Tegretol, etc.)
• Dabrafenib (Tafinlar)
• Dexamethasone (Decadron, etc.)
• Efavirenz (Sustiva)
• Lumacaftor (Orkambi)
• Oxcarbazepine (Trileptal, etc.)
• Phenytoin (Dilantin, etc.)
• Primidone (Mysoline)
• Rifabutin (Mycobutin)
• Rifampin (Rifadin, etc.)
• Rifapentine (Priftin)
• St. John's wort

Comment:

The phosphodiesterase inhibitors are metabolized by CYP3A4 and concurrent administration with CYP3A4 inducers could produce reduced plasma concentrations. Reduced efficacy may occur during coadministered with CYP3A4 inducers. For example,

Class 3: Assess Risk & Take Action if Necessary

• Monitor: Monitor for altered response if the CYP3A4 inducer is initiated, discontinued, or changed in dosage.